{"success":true,"data":{"pressRelease":{"id":"164359","rtpr_id":"nBw3qHX12a-20261008","ticker":"PCRX","exchange":"NASDAQ","all_tickers":["PCRX"],"title":"PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders","author":"Business Wire","published_at":"2026-10-08T12:36:00.128Z","article_body":"PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira\nBioSciences, Inc. is Obtaining a Fair Price for its Shareholders\n\nInsiders may stand to receive substantial financial benefits not available to\nordinary shareholders.\n\nThe proposed transaction may contain terms that could limit superior competing\noffers.\n\nShareholders are encouraged to contact the firm to discuss their rights and\noptions at no cost or obligation. We would handle any matter on a contingent\nfee basis, whereby you would not be responsible for out-of-pocket payment of\nour legal fees or expenses.\n\nHalper Sadeh LLC, an investor rights law firm, is investigating the sale of\nPacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share\nin cash.\n\nHalper Sadeh encourages Pacira shareholders to click here to learn more about\ntheir rights and options\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhalpersadeh.com%2Factions%2Fpacira-biosciences-inc&esheet=54618403&newsitemid=20261008712757&lan=en-US&anchor=click+here+to+learn+more+about+their+rights+and+options&index=1&md5=cc954b47a455ea5287040c8f9b031aa3)\nor contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or\nsadeh@halpersadeh.com (mailto:sadeh@halpersadeh.com) or\nzhalper@halpersadeh.com (mailto:zhalper@halpersadeh.com) .\n\nThe investigation concerns whether Pacira and its board of directors violated\nthe federal securities laws and/or breached their fiduciary duties by failing\nto: (1) obtain the best possible price for Pacira shareholders; (2) conduct a\nfair sales process free of any conflicts of interests; and (3) disclose all\nmaterial information for Pacira shareholders to evaluate the transaction.\n\nOn behalf of shareholders, Halper Sadeh LLC may seek increased consideration,\nadditional disclosures, or other relief and benefits.\n\nHalper Sadeh LLC represents investors all over the world who have fallen\nvictim to securities fraud and corporate misconduct. Our attorneys have been\ninstrumental in implementing corporate reforms and recovering millions of\ndollars on behalf of defrauded investors.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261008712757/en/\n(https://www.businesswire.com/news/home/20261008712757/en/)\n\nHalper Sadeh LLC\nOne World Trade Center\n85th Floor\nNew York, NY 10007\nDaniel Sadeh, Esq.\nZachary Halper, Esq.\n(212) 763-0060\nsadeh@halpersadeh.com (mailto:sadeh@halpersadeh.com) \nzhalper@halpersadeh.com (mailto:zhalper@halpersadeh.com) \nhttps://www.halpersadeh.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.halpersadeh.com&esheet=54618403&newsitemid=20261008712757&lan=en-US&anchor=https%3A%2F%2Fwww.halpersadeh.com&index=2&md5=ffb3d2192fffa73b145649cecb055e2c)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3qHX12a-20261008","title":"PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders","author":"Business Wire","ticker":"PCRX","created":"2026-10-08T12:36:00.128Z","tickers":["PCRX"],"exchange":"NASDAQ","article_body":"PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira\nBioSciences, Inc. is Obtaining a Fair Price for its Shareholders\n\nInsiders may stand to receive substantial financial benefits not available to\nordinary shareholders.\n\nThe proposed transaction may contain terms that could limit superior competing\noffers.\n\nShareholders are encouraged to contact the firm to discuss their rights and\noptions at no cost or obligation. We would handle any matter on a contingent\nfee basis, whereby you would not be responsible for out-of-pocket payment of\nour legal fees or expenses.\n\nHalper Sadeh LLC, an investor rights law firm, is investigating the sale of\nPacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share\nin cash.\n\nHalper Sadeh encourages Pacira shareholders to click here to learn more about\ntheir rights and options\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhalpersadeh.com%2Factions%2Fpacira-biosciences-inc&esheet=54618403&newsitemid=20261008712757&lan=en-US&anchor=click+here+to+learn+more+about+their+rights+and+options&index=1&md5=cc954b47a455ea5287040c8f9b031aa3)\nor contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or\nsadeh@halpersadeh.com (mailto:sadeh@halpersadeh.com) or\nzhalper@halpersadeh.com (mailto:zhalper@halpersadeh.com) .\n\nThe investigation concerns whether Pacira and its board of directors violated\nthe federal securities laws and/or breached their fiduciary duties by failing\nto: (1) obtain the best possible price for Pacira shareholders; (2) conduct a\nfair sales process free of any conflicts of interests; and (3) disclose all\nmaterial information for Pacira shareholders to evaluate the transaction.\n\nOn behalf of shareholders, Halper Sadeh LLC may seek increased consideration,\nadditional disclosures, or other relief and benefits.\n\nHalper Sadeh LLC represents investors all over the world who have fallen\nvictim to securities fraud and corporate misconduct. Our attorneys have been\ninstrumental in implementing corporate reforms and recovering millions of\ndollars on behalf of defrauded investors.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261008712757/en/\n(https://www.businesswire.com/news/home/20261008712757/en/)\n\nHalper Sadeh LLC\nOne World Trade Center\n85th Floor\nNew York, NY 10007\nDaniel Sadeh, Esq.\nZachary Halper, Esq.\n(212) 763-0060\nsadeh@halpersadeh.com (mailto:sadeh@halpersadeh.com) \nzhalper@halpersadeh.com (mailto:zhalper@halpersadeh.com) \nhttps://www.halpersadeh.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.halpersadeh.com&esheet=54618403&newsitemid=20261008712757&lan=en-US&anchor=https%3A%2F%2Fwww.halpersadeh.com&index=2&md5=ffb3d2192fffa73b145649cecb055e2c)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-08T12:36:00.157697843Z","server_sent_at_ms":1791462960157},"received_at":"2026-10-08T12:36:00.208Z","source_url":"https://www.businesswire.com/news/home/20261008712757/en/"},"analysis":{"id":"152779","press_release_id":"164359","analysis_json":{"redFlags":["law firm alleges deal terms may deter superior competing offers","law firm claims insiders may receive benefits not available to ordinary shareholders"],"eventType":"legal_litigation","narrative":"Halper Sadeh LLC, an investor rights law firm, is investigating whether Pacira BioSciences' $36.50-per-share cash sale to Viatris fairly compensates shareholders.\n\nThe firm claims the deal may involve insider benefits, limits on competing offers, and disclosure or fiduciary-duty concerns by Pacira's board.\n\nThis is a law-firm solicitation seeking shareholders to contact the firm on a contingent-fee basis, not a new issuer disclosure or court action; treat as low-signal noise around the pending merger.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine plaintiff-firm investigation of the Pacira/Viatris deal -- suppress; the merger itself is the actionable event."},"keyFigures":{"offeringPrice":36.5,"customDimensions":{"deal_price":"$36.50 per share in cash"}},"namedEntities":{"people":[{"name":"Daniel Sadeh","role":"attorney, Halper Sadeh LLC"},{"name":"Zachary Halper","role":"attorney, Halper Sadeh LLC"}],"products":[],"companies":[{"name":"Pacira BioSciences, Inc.","ticker":"PCRX","relationship":"target"},{"name":"Viatris Inc.","relationship":"acquirer"},{"name":"Halper Sadeh LLC","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$36.50 per share","context":"cash consideration in proposed Viatris acquisition of Pacira"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Halper Sadeh LLC investigating the already-announced Pacira/Viatris merger. No new issuer disclosure, no certified class, no settlement; routine deal-contest marketing."},"tickerRelevance":{"others":[{"ticker":"VTRS","relevance":"acquirer"}],"primary":"PCRX"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":["m_and_a"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingDealRelevance":"pending Viatris acquisition at $36.50/share"}},"event_type":"legal_litigation","event_type_secondary":["m_and_a"],"sentiment":"neutral","material_impact_score":1,"narrative":"Halper Sadeh LLC, an investor rights law firm, is investigating whether Pacira BioSciences' $36.50-per-share cash sale to Viatris fairly compensates shareholders.\n\nThe firm claims the deal may involve insider benefits, limits on competing offers, and disclosure or fiduciary-duty concerns by Pacira's board.\n\nThis is a law-firm solicitation seeking shareholders to contact the firm on a contingent-fee basis, not a new issuer disclosure or court action; treat as low-signal noise around the pending merger.","key_figures":{"offeringPrice":36.5,"customDimensions":{"deal_price":"$36.50 per share in cash"}},"named_entities":{"people":[{"name":"Daniel Sadeh","role":"attorney, Halper Sadeh LLC"},{"name":"Zachary Halper","role":"attorney, Halper Sadeh LLC"}],"products":[],"companies":[{"name":"Pacira BioSciences, Inc.","ticker":"PCRX","relationship":"target"},{"name":"Viatris Inc.","relationship":"acquirer"},{"name":"Halper Sadeh LLC","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$36.50 per share","context":"cash consideration in proposed Viatris acquisition of Pacira"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T12:36:11.344Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingDealRelevance":"pending Viatris acquisition at $36.50/share"}},"durationMs":11135,"modelName":"glm-5.3-flashx"}}